SPORE University of Texas M. D. Anderson Cancer Center-Leukemia

SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病

• 批准号: 10911713
• 负责人: Elizabeth J Shpall
• 金额: $ 91.86万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10911713
• 关键词: ATAC-seq; Achievement; Activated Natural Killer Cell; Acute Myelocytic Leukemia; Acute leukemia; Address; Administrator; Adoptive Transfer; Advocate; Aftercare; Allogenic; Antigens; Award; Azacitidine; B lymphoid malignancy; BCL1 Oncogene; BCL2 gene; Biological Markers; Blood; Blood Proteins; Bone Marrow; CAR T cell therapy; CASP9 gene; CD28 gene; CD70 antigen; Cancer Center; Cancer Center Support Grant; Caring; Cell Death; Cell Differentiation process; Cell Line; Cell Proliferation; Cell Shape; Cell Survival; Cell Therapy; Cell physiology; Cells; Cellular Stress; ChIP-seq; Chemoresistance; Chromatin; Clinic; Clinical; Clinical Protocols; Clinical Trials; Collaborations; Communication; Complement; Complex; Consultations; Cryopreservation; Cytarabine; Cytoplasm; DNA; Data; Databases; Dependence; Development; Disease; Disease remission; Doctor of Medicine; Dose; Doxorubicin; Drug Targeting; EZH2 gene; Electronic Mail; Eligibility Determination; Endogenous Retroviruses; Endowment; Engineering; Enrollment; Ensure; Event; Exhibits; Exposure to; FLT3 inhibitor; Future; Gene Silencing; Generations; Genes; Genetic Transcription; Genotype; Goals; Good Manufacturing Process; Grant; Hematologic Neoplasms; Hematopoietic stem cells; Hodgkin Disease; Human; IL3RA gene; In Vitro; In complete remission; Induction of Apoptosis; Infrastructure; Institution; Institutional Review Boards; Interferons; Interleukin-15; Laboratories; Leukemic Cell; Ligands; Liposomes; Lymphoid Cell; Maintenance; Marrow; Measures; Metabolic; Metabolism; Methods; Minority; Mitochondrial Electron Transport Complex I; Modality; Modeling; Monitor; Morphology; Multiple Myeloma; Mus; Mutation; National Cancer Institute; Natural Killer Cells; Nature; Neoadjuvant Therapy; Oncogenes; Organ; Outcome; Oxidative Phosphorylation; Pathogenesis; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phase I/II Clinical Trial; Phenotype; Phosphorylation Inhibition; Play; Policies; Population; Postremission Therapy; Preclinical Testing; Predisposition; Preparation; Prognosis; Progress Reports; Proliferating; Protein Array; Proteomics; Protocols documentation; Publications; Publishing; RNA; Refractory; Regulation; Relapse; Relaxation; Reporting; Reproduction spores; Research; Research Personnel; Research Project Grants; Residual Neoplasm; Residual state; Resistance; Retrotransposon; Risk; Safety; Sampling; Serum; Signal Transduction; Site; Specimen; Stem cell transplant; Strategic Planning; Stress; T-Lymphocyte; TNF gene; Testing; Texas; Therapeutic; Tissues; Toxic effect; Transcription Elongation; Transcription Initiation; Translational Research; Treatment Efficacy; Tumor Antigens; Tumor Burden; Umbilical Cord Blood; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Up-Regulation; Woman; Work; acute myeloid leukemia cell; adverse outcome; antileukemic activity; biobank; biological adaptation to stress; career; cell killing; cellular transduction; chemotherapeutic agent; chemotherapy; chimeric antigen receptor; cohort; cost; cytopenia; design; drug development; drug testing; ds-DNA; efficacy testing; engineered NK cell; experience; experimental study; first-in-human; genetically modified cells; graft vs host disease; improved; improved outcome; in vitro activity; in vitro testing; in vivo; inhibitor; inhibitor therapy; lectures; leukemia; leukemia relapse; leukemia treatment; leukemic stem cell; lymphoid neoplasm; manufacture; manufacturing process; meetings; member; mesenchymal stromal cell; metabolic fitness; mitochondrial fitness; mouse model; nanomolar; neoplastic cell; next generation; novel; novel therapeutics; older patient; overexpression; partial response; patient derived xenograft model; peripheral blood; pharmacodynamic biomarker; pharmacologic; point of care; prevent; progenitor; programs; prospective; protein expression; receptor; recruit; relapse patients; repository; response; screening; sensor; single cell analysis; small molecule; standard care; stem cells; success; suicide gene; symposium; synergism; targeted therapy trials; tool; transcriptome sequencing; transcriptomics; transplantation therapy; tumor; tumor heterogeneity; vector; weapons; web site

Project Abstract N/A

项目摘要 N/A

项目成果

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

• DOI: 10.1158/1078-0432.ccr-16-1904
• 发表时间: 2017-07-01
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Han L;Jorgensen JL;Brooks C;Shi C;Zhang Q;Nogueras González GM;Cavazos A;Pan R;Mu H;Wang SA;Zhou J;Ai-Atrash G;Ciurea SO;Rettig M;DiPersio JF;Cortes J;Huang X;Kantarjian HM;Andreeff M;Ravandi F;Konopleva M
• 通讯作者: Konopleva M

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

• DOI: 10.1007/s10637-011-9660-2
• 发表时间: 2012-06
• 期刊: INVESTIGATIONAL NEW DRUGS
• 影响因子: 3.4
• 作者: Kantarjian, H. M.;Padmanabhan, S.;Stock, W.;Tallman, M. S.;Curt, G. A.;Li, J.;Osmukhina, A.;Wu, K.;Huszar, D.;Borthukar, G.;Faderl, S.;Garcia-Manero, G.;Kadia, T.;Sankhala, K.;Odenike, O.;Altman, J. K.;Minden, M.
• 通讯作者: Minden, M.

Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

• DOI: 10.1038/s41375-020-0758-4
• 发表时间: 2020-09
• 期刊: Leukemia
• 影响因子: 11.4
• 作者: Kayser S;Rahmé R;Martínez-Cuadrón D;Ghiaur G;Thomas X;Sobas M;Guerci-Bresler A;Garrido A;Pigneux A;Gil C;Raffoux E;Tormo M;Vey N;de la Serna J;Salamero O;Lengfelder E;Levis MJ;Fenaux P;Sanz MA;Platzbecker U;Schlenk RF;Adès L;Montesinos P
• 通讯作者: Montesinos P

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

• DOI: 10.1038/onc.2009.7
• 发表时间: 2009-04-09
• 期刊: Oncogene
• 影响因子: 8
• 作者: Samanta AK;Chakraborty SN;Wang Y;Kantarjian H;Sun X;Hood J;Perrotti D;Arlinghaus RB
• 通讯作者: Arlinghaus RB

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

• DOI: 10.1038/leu.2016.393
• 发表时间: 2017-09
• 期刊: Leukemia
• 影响因子: 11.4
• 作者: Saenz DT;Fiskus W;Qian Y;Manshouri T;Rajapakshe K;Raina K;Coleman KG;Crew AP;Shen A;Mill CP;Sun B;Qiu P;Kadia TM;Pemmaraju N;DiNardo C;Kim MS;Nowak AJ;Coarfa C;Crews CM;Verstovsek S;Bhalla KN
• 通讯作者: Bhalla KN